Entrada Therapeutics, Inc. (TRDA)
NasdaqGM · USD · Healthcare · Biotechnology
$4.75 (+7.71%) as of
Key statistics
- Market cap
- 184.95M
- Forward P/E
- -1.58
- EPS (TTM)
- -3.9600
- Dividend yield
- 0.00%
- 52-week range
- 4.1090 – 16.4500
- Beta
- -0.24
- Revenue (TTM)
- 4.69M
- Profit margin
- 0.00%
- Analyst target
- $19.00
- Volume
- 617.09k
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 152
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.